Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT05045664

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

The MIR study proved the effect of Rituximab in combination with a localized irradiation given in a standard dose. Together with the TROG 99.03 trial, this led…

Germany100 participantsStarted 2022-07-06

Treatment: Standard, Experimental

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

All recent trials (1 shown)